Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas

PHASE4CompletedINTERVENTIONAL

Enrollment

101

Participants

Timeline

Start Date

March 1, 2016

Primary Completion Date

February 10, 2018

Study Completion Date

February 28, 2018

Conditions

Type 2 Diabetes MellitusProteinuria

Interventions

DRUG

Dipeptidyl Peptidase 4 Inhibitor

Vildagliptin 50 milligrams twice daily in addition to metformin 1000 milligrams once daily

DRUG

Sulfonylurea

Glimepiride 2 milligrams twice daily in addition to metformin 1000 milligrams once daily

All Listed Sponsors

lead

Changhua Christian Hospital

OTHER

NCT03983551 - Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas | Biotech Hunter | Biotech Hunter